Heilongjiang Net News (Li Yanqun, Liu Rui, Reporter Wang Zhongyan) Recently, the National Natural Science Foundation of China announced the evaluation results of the 2024 National Natural Science Foundation of China. Harbin Medical University Cancer Hospital has made new breakthroughs, with a total of 28 projects approved, an increase of 40% over last year and a record high. Among them, there are 10 general projects and 18 youth science funds, with a total direct funding of 10.27 million yuan.
The National Natural Science Foundation of China plays an important role in promoting the construction of disciplines and cultivating outstanding scientific and technological talents. In recent years, Harbin Medical University Cancer Hospital has attached great importance to the introduction and training of talents, and has increased investment in talent training, platform construction and scientific research.
National Natural Science Foundation of China
Han Fei
SIRT3 deSUMOylation inhibits the brain-protective effect of MCU-mediated calcium overload in the context of ECPB-controlled reperfusion resuscitation in accidental cryogenic cardiac arrest (National Natural Science Foundation of China)
Director of the Department of Anesthesiology, Affiliated Cancer Hospital of Harbin Medical University
Director of the Department of Anesthesiology, Affiliated Cancer Hospital of Harbin Medical University
Director of Heilongjiang Provincial Clinical Research Center for Anesthesiology
Professor, Researcher, Chief Physician, Doctoral Supervisor
Heilongjiang Province returned from studying abroad to introduce talents, leader of key specialty construction projects in Heilongjiang Province, founder of · Harbin Public Welfare Academic Organization of Cardiopulmonary Resuscitation.
He is currently the chairman of the Perioperative Rehabilitation Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesia, the vice chairman of the Tumor Anesthesia and Analgesia Committee of the Chinese Anti-Cancer Association, the vice chairman of the Thoracic Anesthesia Branch of the Chinese Society of Cardiothoracic and Vascular Anesthesia, and the member of the Anesthesiology Branch of the Chinese Medical Association.
Mainly engaged in cardiopulmonary and cerebral resuscitation related research, won the second prize of the Provincial Natural Science Award (the first completer); It has been supported by 14 projects, including 4 projects from the National Natural Science Foundation of China and 1 provincial key research and development plan; He has published 60 articles, 37 of which are included in SCI; He has compiled 6 national guidebooks and participated in the compilation of 5 national planning textbooks and monographs.
Sun Yihua
Mechanism and Clinical Value of Calcium-Sensing Receptor-mediated Neutrophil Exosomes Carrying THBS1 to Promote Atherosclerosis (National Natural Science Foundation of China)
Director of the Department of Clinical Laboratory, Affiliated Cancer Hospital of Harbin Medical University
Director of the Department of Laboratory Diagnostics of the Affiliated Cancer Hospital of Harbin Medical University
Chief physician, second-level professor, doctoral supervisor
He is currently the chairman of the Tumor Marker Special Committee of the Heilongjiang Anti-Cancer Association, the standing committee member of the Tumor Marker Special Committee of the Chinese Anti-Cancer Association, the standing member of the Tumor Clinical Laboratory and Companion Diagnosis Special Committee of the Chinese Anti-Cancer Association, and the vice chairman of the Heilongjiang Provincial Laboratory Branch of the Chinese Medical Association.
He is mainly engaged in the research of the role and mechanism of receptor proteins in cardiovascular diseases and tumor heart disease. He has presided over more than 10 projects of the National Natural Science Foundation of China, more than 10 sub-projects of "863", and the Provincial Natural Science Foundation, and published more than 70 SCI and core journal papers.
Geng Feng
Effect and mechanism of NPC-mediated cholesterol transport combined with SREBP-2 inhibitor in the treatment of glioblastoma (National Natural Science Foundation of China)
Professor of Scientific Research Center, Affiliated Cancer Hospital of Harbin Medical University
Professor of Heilongjiang Provincial Key Laboratory of Molecular Oncology
Professor, doctoral supervisor
He is a member of the United States Oncology Association, a member of the United States Neuro-Oncology Society, and a reviewer of academic journals such as Nature Communications.
He focuses on the molecular mechanism and clinical translational research of targeted lipid metabolism, especially cholesterol metabolism in the treatment of tumors. He has published more than 20 articles in journals such as Cell Metabolism, Cell Reports, Autophagy, etc., with more than 2,000 citations, and the highest single citation is more than 600 times.
Yuan Zhennan
Mechanism of CCL2-mediated O-GlcNAc glycosylation of PGK1 to induce metabolic reprogramming of CAFs to promote anti-PD-1 immunotherapy resistance in head and neck cancer (National Natural Science Foundation of China)
Deputy Chief Physician of the Second Ward of Head and Neck Surgery, Department of Nose and Neck, Affiliated Cancer Hospital of Harbin Medical University
Secretary of the Party Branch of the Department of Head and Neck Surgery, Affiliated Cancer Hospital of Harbin Medical University
Deputy Chief Physician, Associate Professor
He is currently a member of the Head and Neck Tumor Professional Committee of China Medical Education, and the leader of the Youth Group of the Head and Neck Tumor Special Committee of Heilongjiang Medical Association.
He presided over the projects of the Natural Science Foundation of Heilongjiang Province and the Provincial Health Commission, published several SCI papers as the first author or corresponding author, and participated in the research and development of a number of patent achievements.
Lebo
Mechanism of "TNNT1-VHL-FASN" Axis Promoting Palmitic Acid Production and Inhibiting CD8+ T Cell Killing Function in Dry Cells of Triple-negative Breast Cancer Tumors and Mediating Immunotherapy Resistance (National Natural Science Foundation of China)
Chief Physician of the Second Breast Surgery Ward of the Affiliated Cancer Hospital of Harbin Medical University
Chief Physician, Professor, MD, Postdoctoral Fellow
Member of the expert group of the Breast Cancer Single Disease Hierarchical Diagnosis and Treatment Special Disease Alliance of the Health Development Research Center of the National Health Commission; Member of the Expert Committee on Oncology and Cardiology of the Geriatric Oncology Branch of the Chinese Society of Gerontology and Geriatrics; Member of the Expert Committee for Health Technology Promotion of China National Health Association; Member of the Breast Cancer Professional Committee of Heilongjiang Anti-Cancer Association.
The research focuses on CSCs, tumor metabolism, and drug resistance. As the first author or corresponding author, he has published 10 SCI papers, with the highest impact factor of 17.66 for a single paper, and presided over 7 scientific research projects at all levels.
Xu Shouping
Molecular Mechanism of NAT10 Up-regulation of GPX4 Expression and Reduction of Paclitaxel Sensitivity in Breast Cancer through Ac4C Modification and TINCR-mediated Epiregulation (National Natural Science Foundation of China)
Director of the First Breast Surgery Ward of the Affiliated Cancer Hospital of Harbin Medical University
Director of Heilongjiang Provincial Key Laboratory of Cancer Biotherapy
Doctor of Medicine, Chief Physician, Researcher, Doctoral Supervisor
High-level talent in Heilongjiang Province, professor of Salient of Harbin Medical University. He is a member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, a member of the Oncology and Lymphedema Branch of the Chinese Anti-Cancer Society, a youth member of the Oncology Branch of the Chinese Medical Association, and a communication review expert of the National Natural Science Foundation of China.
He has presided over 4 projects of the National Natural Science Foundation of China and 1 key R&D program of Heilongjiang Province. He has published papers in JCR Zone 1 journals such as Nature Communications, Autophagy, Cancer Immunology Research, etc., with a citation frequency of 1700 times and a single citation of 5 papers > 100 times. He has won the first prize of Heilongjiang Provincial Science and Technology Progress Award, Heilongjiang Provincial Medical and Health Science and Technology Award, Heilongjiang Provincial Youth Science and Technology Award, Heilongjiang Provincial Medical and Health New Technology Application Award and other awards, and was selected into the 2021 National Top 100 Breast Cancer Experts Academic Influence List (Top66).
Cai Li
Study on the regulation of mitochondrial localization by splice factor SF3B4 to promote lung adenocarcinoma metastasis and cisplatin resistance (National Natural Science Foundation of China)
Director of the Second Ward of the Department of Breast Medicine, Affiliated Cancer Hospital of Harbin Medical University
Second-level professor, doctoral supervisor
He is a member of the Standing Committee of the Multi-Primary and Unknown Primary Tumors Professional Committee of the Chinese Anti-Cancer Association, a member of the Breast Cancer Professional Committee of the Chinese Anti-Cancer Association, a member of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association, and a review expert of the National Natural Science Foundation of China.
He is committed to the research of tumor metastasis, chemotherapy resistance and immunotherapy resistance. He has won 6 national natural projects, 7 provincial and ministerial scientific and technological achievement awards, and published 64 SCI papers as the corresponding author or first author, with a cumulative impact factor of 273.196.
Yao Yuanfei
Mechanism of TRIM38 Inhibition of Mitochondrial Energy Metabolism and Increasing the Sensitivity of Bladder Cancer Cells to PD-1 Monoclonal Antibody (National Natural Science Foundation of China)
Associate researcher of the Second Ward of Gastroenterology, Affiliated Cancer Hospital of Harbin Medical University
Associate researcher, master's supervisor
She is a member of the Clinical Oncology Professional Committee of the Chinese Women Physicians Association, and the vice chairman of the Biological Therapy Professional Committee of the Heilongjiang Anti-Cancer Association.
His research interests include the mechanism of resistance to tumor immunotherapy and related translational studies. He has published 8 SCI papers as the corresponding author, and the highest impact factor of a single paper is 27.4. He has presided over 2 projects of the National Natural Science Foundation of China, 1 project of the Provincial Natural Science Foundation, and 1 project of China Postdoctoral Fund and 1 Provincial Postdoctoral Fund. He has won 1 first prize of the Provincial Government Science and Technology Progress Award (ranked fifth) and 1 national invention patent (ranked fifth).
Ye Leiguang
Mechanism of Exosome PRPS1 in Triple Negative Breast Cancer Mediated Immunotherapy Resistance by Inhibiting CD8+ T Cell Killing Function through IDO1/Khn Axis (National Natural Science Foundation of China)
Chief physician of the first ward of the Department of Respiratory Medicine, Affiliated Cancer Hospital of Harbin Medical University
Doctor of Medicine, Chief Physician, Associate Professor, Master's Supervisor
He is a member of the Standing Committee of the Lung Cancer Professional Committee of the Heilongjiang Chronic Disease Management Association, a member of the Standing Committee of the Tumor Precision Treatment Branch of the Heilongjiang Association of Integrative Traditional and Western Medicine, a member of the Breast Disease Professional Committee of the Heilongjiang Medical Doctor Association, and a member of the Heilongjiang Chronic Disease Lung Cancer Professional Committee.
Focusing on the research of tumor microenvironment and immunotherapy resistance mechanism, he has published more than 10 SCI papers as the first author or corresponding author, with the highest impact factor of 21.3 for a single paper, and presided over 6 scientific research projects at all levels. The deputy editor-in-chief published an undergraduate planning textbook of the People's Medical Publishing House, and the editor-in-chief published a monograph of the national first-class publishing house.
Miao Susheng
Study on CTSL inhibiting the proliferation and activation of CD8+ T cells in laryngeal cancer by down-regulating CXCL16-CXCR6 to lead to PD-1 monoclonal antibody treatment tolerance (National Natural Science Foundation of China)
Deputy Director of the First Ward of the Department of Head and Neck Surgery, Department of Surgery, Affiliated Cancer Hospital of Harbin Medical University (in charge)
Chief physician, professor, master's supervisor, doctor of oncology, postdoctoral fellow in genetics
He is currently the chairman of the Head and Neck Tumor Professional Committee of Heilongjiang Anti-Cancer Association, the chairman of the Head and Neck Tumor Professional Committee of Heilongjiang Medical Association, the vice chairman of the Head and Neck Tumor Professional Committee of the China Medical Education Association, and the member of the Head and Neck Tumor Professional Committee of the China Anti-Cancer Association.
His main research interests include changes in the immune microenvironment of head and neck squamous cell carcinoma and metabolic reprogramming of thyroid cancer. presided over 8 scientific research projects at all levels; Won 1 first prize and 1 third prize of Heilongjiang Provincial Medical and Health New Technology; He has published more than 20 SCI papers as the first author or corresponding author. He was awarded the advanced individual of "three educations" in education and teaching of Harbin Medical University, the chief expert of the advantageous discipline (head and neck tumor) of the "Climbing Plan" of Harbin Medical University Cancer Hospital, and the director of the excellent department of Harbin Medical University Cancer Hospital.
National Natural Science Foundation of China, Young Scientist Foundation Project
Liu Siqi
Immunotherapy Target Identification and Drug Screening in ICC Patients Based on Single-Cell Omics Data and GCN-Transformer Model (National Natural Science Foundation of China Young Scientist Foundation of China)
Attending physician of the Second Ward of Gastroenterology, Affiliated Cancer Hospital of Harbin Medical University
M.D., Attending Physician
He is currently the secretary of the Biliary Tract Tumor Professional Committee of Heilongjiang Anti-Cancer Association.
His research interests include the mechanism of the occurrence and development of digestive system tumors and the exploration of new combination treatment regimens. As the first and co-first author, he has published 10 SCI papers in journals such as Hepatology, Cancer letters, Briefings in Bioinformatics, Star Protocols, etc., and presided over 2 provincial projects.
Li Zhange
Mechanism of tRF-29-PNR8YP9LONHK in Improving Endothelial Cell Ferroptosis after Atherosclerosis by Regulating DHX33 and Histone H3K18 Lactation (National Natural Science Foundation of China Young Scientist Foundation of China)
Pharmacist in charge of the Department of Pharmacy of the Affiliated Cancer Hospital of Harbin Medical University
Doctor of Pharmacy, Pharmacist in Charge
He is currently the secretary-general of the Applied Pharmacology Committee of the Heilongjiang Pharmaceutical Association and a member of the Pharmacy Committee of the Harbin Pharmaceutical Association.
His main research interests are pathogenesis and translational research of cardiovascular diseases and tumor-related cardiovascular diseases. In the past five years, he has published a SCI paper in the journal Cell Death & Disease as the first author. He has presided over 3 scientific research projects at all levels.
Li Shuang
Research on the regulation of macrophage polarization in the treatment of severe acute pancreatitis based on monocyte membrane-hair follicle stem cell exosomes (National Natural Science Foundation of China Youth Science Foundation Project)
Attending physician of the Second Ward of Gastroenterology, Affiliated Cancer Hospital of Harbin Medical University
MD, Postdoctoral Fellow
He was awarded the "President Wu Liande Award" of Harbin Medical University, an outstanding talent position, and was selected into the state-funded postdoctoral researcher program. He is mainly engaged in the diagnosis and treatment of digestive system tumors. In recent years, he has published 2 SCI papers as the first author, participated in the publication of 6 SCI papers, and presided over 7 scientific research projects at all levels.
Wang Qiucheng
Model Study on Early Prediction of NAC Efficacy of Breast Cancer Based on ABUS and Clinical Data Based on Deep Learning (National Natural Science Foundation of China Young Scientist Foundation Project)
Deputy Chief Physician of the Department of Ultrasound Medicine, Affiliated Cancer Hospital of Harbin Medical University
Doctor of Medicine, Postdoctoral Fellow, Associate Professor, Master Supervisor
He is currently a member of the Tumor Ultrasound Therapy Committee of the China Anti-Cancer Association, and a member of the Artificial Intelligence and Molecular Imaging Committee of the Sonographer Branch of the China National Health Association.
His research interests include interventional ultrasound, artificial intelligence and ultrasound molecular imaging. In the past five years, he has published 6 SCI papers in European Radiology, BMC cancer and other journals as the first author and corresponding author, and presided over a number of scientific research projects.
Wang Jiaqi
A New Strategy to Inhibit the Recurrence of Bladder Cancer after Surgery: Screening, Optimization and Mechanism of Self-assembled Nuclide Diagnostic Probes Based on Microbial Simulation (National Natural Science Foundation of China Young Scientist Foundation of China)
Assistant researcher of the Third Ward of Urology, Affiliated Cancer Hospital of Harbin Medical University
MD, Research Associate
He is a visiting scholar at the National University of Singapore and a doctoral fellow at the National Center for Nanoscience. He is currently a member of the Medical Engineering Integration Committee of the Chinese Anti-Cancer Association and a member of the Tumor Clinical Laboratory and Companion Diagnosis Professional Committee of the Chinese Anti-Cancer Association.
He has long been committed to the research of precision diagnosis and treatment of urological tumors. In recent years, he has published a total of 20 SCI papers, and 9 SCI papers have been published as the first (including tied) authors in international authoritative journals such as Advanced Materials (3 papers) and Angewandte Chemie. A total of 8 scientific research projects have been obtained, and 3 projects at or above the provincial and ministerial level have been obtained. 1 national invention patent has been authorized.
Sun Yige
Non-invasive c-MET mutation typing diagnosis and targeted therapy sensitivity restratification of NSCLC based on CNN-Transformer and anti-transfer learning (National Natural Science Foundation of China for Young Scientists)
Physician of the Imaging Center of the Affiliated Cancer Hospital of Harbin Medical University
MD, Postdoctoral Fellow
He was selected into the state-funded postdoctoral researcher program and the outstanding talent of Harbin Medical University.
His main research direction is precision diagnosis and treatment of lung cancer at the molecular level. As the first author and co-author, he has published 7 SCI papers, presided over and participated in a number of national projects, and won the second place in the English speech competition of the 30th National Conference on Radiology (CCR2023) of the Chinese Medical Association.
Guo Pengyu
Study on Interface Responsive Gel Probe Targeting Type I Collagen on Tumor Surface for Intraoperative Navigation in Non-Muscle Invasive Bladder Cancer (National Natural Science Foundation of China Young Scientist Foundation of China)
Deputy Chief Physician of the Third Ward of Urology, Affiliated Cancer Hospital of Harbin Medical University
Deputy Chief Physician, Associate Professor, Master's Supervisor
He is currently the vice chairman of the Urology Youth Committee of the Heilongjiang Medical Promotion Association, a member of the Tumor Artificial Intelligence Professional Committee of the China Anti-Cancer Association, a member of the Urology Branch of the Heilongjiang Association of Integrative Traditional and Western Medicine, and a member of the Heilongjiang Andrology Association.
Focusing on the clinical direction of diagnosis and treatment of bladder cancer, systematic and multidisciplinary interdisciplinary research has been carried out. In the past five years, he has published 7 SCI papers with relevant achievements as the first/corresponding author, with a cumulative impact factor of more than 50, authorized 3 national invention patents, guided students to participate in the 2022 and 2024 United States Collegiate Mathematical Contest in Modeling and won the second prize (Honorable Mentioned), and presided over 3 scientific research projects at all levels.
Xu Jingjing
Mechanism of Immunosuppression of Sepsis Induced by C/EBPβ Induction of Palmitoylation by ZDHHC7 Palmitoylation (National Natural Science Foundation of China Young Scientist Foundation of China)
Deputy Chief Physician of the Department of Critical Care Medicine, Affiliated Cancer Hospital of Harbin Medical University
Associate Professor, Deputy Chief Physician, Master's Supervisor
His research focuses on the immunosuppressive mechanism of sepsis. He has been a visiting scholar at East Tennessee State University in United States, presided over 1 provincial project in Heilongjiang Province, participated in the publication of 6 sepsis-related SCI papers, published 4 articles as the first author, and published representative studies in J Microbiol Immunol Infect, J Inflamm Res and other journals, with a total impact factor of 61.809.
Ding Chujie
Mechanism of deoxycholic acid inhibition of CD8+ T cell function and promotion of colon cancer progression through PGC-1α/HIF-1α-mediated mitochondrial kinetic imbalance (National Natural Science Foundation of China Young Scientist Foundation of China)
Assistant researcher of the Scientific Research Center of the Affiliated Cancer Hospital of Harbin Medical University
Doctor of Pharmacy, Assistant Researcher
He is mainly engaged in the study of the anti-tumor immune regulation mechanism of endogenous metabolites. He has presided over a number of projects such as the Heilongjiang Provincial "Longjiang Excellent Master's and Doctoral Dissertations in the New Era" Fund and the Haiyan Scientific Research Fund. He has published 2 papers as the first and joint first author, participated in the publication of 9 papers and 1 patent.
Fang Tianyi
Study on the Mechanism of Intracellular/Extracellular Inhibition of Tumor Metastasis by Gastric Cancer Lymphatic Metastasis Related Gene FGFBP1 (National Natural Science Foundation of China Young Scientist Foundation of China)
Attending physician of the first ward of gastrointestinal surgery of the Affiliated Cancer Hospital of Harbin Medical University
M.D., Attending Physician
His main research interests are the molecular mechanism of gastric cancer metastasis and clinical translational therapy. He has won the National Scholarship for Doctoral Students, presided over 4 scientific research projects at all levels, published 16 SCI papers as the first author and co-first author, participated in the compilation of a monograph of a national publishing house, and won a national first-class undergraduate course as a speaker.
Pan Bo
Mechanism of RBM10/KDM5A/WNT5A Axis Regulating Fatty Acid Metabolism Reprogramming to Promote Brain Metastasis of Lung Adenocarcinoma (National Natural Science Foundation of China Young Scientist Foundation of China)
Deputy Chief Physician of the Third Ward of the Department of Respiratory Medicine, Affiliated Cancer Hospital of Harbin Medical University
Doctor of Medicine, Deputy Chief Physician, Associate Professor, Master's Supervisor
He is currently a member of the Standing Committee/Secretary of the Lung Cancer Professional Committee of the Heilongjiang Medical Doctor Association, the deputy head of the Regional Group of the Cancer Palliative Care Branch of the Heilongjiang Medical Association, a member of the Lung Cancer Youth Professional Committee of the Heilongjiang Medical Doctor Association, and a member of the Tumor Rehabilitation Professional Committee of the Heilongjiang Rehabilitation Medical Association.
He is mainly engaged in research on tumor microenvironment and tumor metastasis, published 5 SCI papers as the first author and corresponding author (including co-author), participated in 3 national natural projects and 1 provincial key project.
Pia male
Mechanism of CDK4-GCN5 Enhanced MCL1 Succylation Modification in Promoting Serous Ovarian Cancer Progression and Cisplatin Resistance (National Natural Science Foundation of China Young Scientist Foundation of China)
Attending physician of the first ward of gynecology of the Affiliated Cancer Hospital of Harbin Medical University
M.D., Attending Physician
His research focuses on the molecular mechanism of the occurrence and development of gynecological malignant tumors. Won the 2023 "Longjiang Excellent Doctoral Dissertation in the New Era"; Received the National Postdoctoral Fellowship C; He has presided over 1 postdoctoral project in China. He has published 5 SCI papers as the first author.
Cao Mengru
Study on the regulation of mitochondrial spatial distribution by m5C writer NSUN5 to promote lung adenocarcinoma metastasis (National Natural Science Foundation of China Young Scientist Foundation Project)
Chief physician of the Second Ward of the Department of Breast Medicine, Affiliated Cancer Hospital of Harbin Medical University
Doctor of Medicine, Chief Physician, Professor
She is currently a member of the Multiple Primary and Unknown Primary Tumor Special Committee of the Chinese Anti-Cancer Association, a member of the Breast Special Committee of the Chinese Women Physicians Association, the director-elect of the Multiple Primary and Unknown Primary Tumors Special Committee of the Heilongjiang Anti-Cancer Association, and the vice chairman of the Breast Tumor Special Committee of the Heilongjiang Women Physicians Association.
His current research interests include m5C methylation modification in regulating lung adenocarcinoma progression and the study of multiple primary tumors. He has published 8 SCI articles as the first author or corresponding author, and has undertaken 6 projects such as China Postdoctoral Science Foundation and Heilongjiang Provincial Natural Science Foundation.
Wang Yan
Mechanism of GSDME-mediated chemotherapy for pyroptosis sensitized cholangiocarcinoma by targeting IL-6/TSPAN1 signaling (National Natural Science Foundation of China)
Deputy Chief Physician of the Second Ward of Colorectal Surgery, Affiliated Cancer Hospital of Harbin Medical University
Doctor of Medicine, Deputy Chief Physician
He is engaged in the diagnosis, treatment and scientific research of digestive tract tumor diseases. Awarded the National Scholarship for Doctoral Studies; He has published more than 10 SCI articles, of which the first author and co-first author have published 6 SCI articles in journals such as Journal of Experimental & Clinical Cancer Research. He has presided over 4 scientific research projects at all levels.
Li Xianjun
Study on the Efficacy of Tumor-Targeted Bacterial Outer Membrane Vesicles to Enhance the Anti-Solid Tumor Efficacy of CAR-T Cells by In Situ Antigen Modification (National Natural Science Foundation of China Young Scientist Foundation of China)
Physician of the Fourth Ward of Breast Surgery, Affiliated Cancer Hospital of Harbin Medical University
MD, Postdoctoral Fellow
His research interests are the application of CAR-T cell therapy in solid tumors. He has published papers in Advanced Materials, Hepatology and other journals as the first or co-author, authorized two national invention patents, won the excellent doctoral dissertation of Sun Yat-sen University, outstanding graduates, was selected into the postdoctoral innovative talent support program, and was funded by the National Natural Youth Fund and the China Postdoctoral Project.
Juniper Tao
PAR1 inhibitor vorapasa sensitizes coloroptosis in colorectal cancer tumor cells by activating the FOXO1/HMOX1 signaling axis (National Natural Science Foundation of China Young Scientist Foundation of China)
Attending physician of the first ward of colorectal surgery, Affiliated Cancer Hospital of Harbin Medical University
M.D., Attending Physician
目前从事肿瘤免疫以及细胞死亡方面研究，主持各级各类科研课题2项，以第一作者在Signal Transduction and Targeted Therapy等期刊发表SCI论文5篇。
Li Wei
Mechanism of Ilismo Enhancing Anti-PD-1/PD-L1 Therapeutic Sensitivity of Triple Negative Breast Cancer by Inducing Cuproposis (National Natural Science Foundation of China Young Scientist Foundation Project)
Physician of the Second Ward of the Department of Head and Neck Surgery, Department of Surgery, Affiliated Cancer Hospital of Harbin Medical University
M.D., Attending Physician
He is engaged in research in the field of tumor treatment resistance, and has published several SCI-indexed papers in journals such as Molecular Cancer as the first author.
Shi Jiaqi
Mechanism of Electroacupuncture Activation of β-arrestin 1/IFN Pathway to Promote "Cold-Heat" Immunophenotypic Transformation and IDO Inhibitors in the Treatment of MSS Colorectal Cancer (National Natural Science Foundation of China Young Scientist Foundation of China)
Attending physician of Phase I Clinical Research Center, Cancer Hospital Affiliated to Harbin Medical University
M.D., Attending Physician
His main research direction is the role of STING in the sensitization of immunotherapy for digestive system tumors. As the first author (including tied), he has published 7 SCI papers in journals such as Hepatology and Cancer Immunol Res, presided over 5 scientific research projects at all levels, and authorized 1 invention patent.
The continuous growth of the National Natural Science Foundation of China has prompted the staff of the hospital to unswervingly move forward towards a research hospital that achieves high-quality development and continues to climb towards the peak of oncology medicine.